Cell Membrane-Coated Nanoparticles: A New Frontier in Targeted Drug Delivery

by

Introduction

Over the past several years, a fairly innovative area within drug delivery has been identified, namely cell membrane-coated nanoparticles (CM-NPs). These nanoscale assemblies incorporate biological cell membranes’ features with the adaptability of nanoparticles, providing for prospective treatment systems, including target medications’ delivery. Through silicification of nanoparticles with cell membranes extracted from a range of cell types, researchers have provided themselves with biocompatible, immune-avoidance systems that move around the body more efficiently than simple synthetic nanoparticles. This approach goes further in increasing the effectiveness of delivery of therapeutic agents to targeted disease sites while at the same time reducing both side effects and general treatment results. In this article, a detailed description of CM-NPs is done, and the distribution mode of this unique drug delivery system is explained in great detail along with its relevance in revolutionizing the current delivery systems.

The Concept of Cell Membrane Coating

The number of cell membrane coatings is a technique that has been developed to coat nanoparticles with the natural cell membrane that is harvested from various types of cells, including red blood cells, platelets, cancer cells, and immune cells. In this biomimetic strategy, the cell membranes are used, and their antigenic markers, biocompatibility, and homotypic targeting properties are involved to produce a nanoparticulate system capable of a compatible interaction with the biological milieu. The attachment of cell membranes on nanoparticle surfaces imparts these structures with a ‘cover’ that improves immune avoidance, circulation time, and targeting ability.

Moreover, the RBC membrane-coated nanoparticles, such as RBCs, benefit from their nontoxic characteristic and ability to circulate in the bloodstream for a long time without being recognized by the immune system. Thus, the incorporation of this natural asset in biomedicine translates to a longer circulation half-life, reduced clearance by the immune system, and better drug delivery efficiency in RBC-coated nanoparticles. In the same manner, cancer cell membrane-coated nanoparticles take advantage of the homotypic targeting ability that leads to high interaction of these nanoparticles with tumors with similar antigens to the source cancer cells, enhancing the specificity of therapy.

Yearwise Publication Trend on “drug delivery”

Find publication trends on relevant topics

Mechanisms of Action

The greatest strength of CM-NPs is in the fact that they can take on the functions of natural cells and perform particular activities with target tissues. The coating process maintains all exterior proteins, receptors, and functional characteristics of the original cells that significantly influence the nanoparticles’ behavior in a living organism. For instance, on the RBC membrane, a ‘do not eat me signal called CD47 that binds to the inhibitory receptor SIRP-alpha on macrophages prevents immune clearance. Similarly, in cancer cell membrane-coated nanoparticles, the surface antigens on the surface of the nanoparticles stem from the source tumor, thereby allowing the nanoparticles to selectively identify cells similar to the tumor.

Generally, the coating process involves the delamination of cell membranes around nanoparticle cores, such as polymeric, gold, or mesoporous silica nanoparticles. This membrane coating not only improves the biocompatibility of nanoparticles but also provides the opportunity to incorporate more targeting ligands, drugs, or imaging agents; thus, these nanoparticles are very suitable for therapeutic and diagnostic uses.

Applications in Cancer Therapy

From all applications of CM-NPs, cancer therapy stands out as the most effective area of improvement, as CM-NPs aid in enhancing the targeting and overall effectiveness of anticancer therapies. As many patients suffer from systemic and toxic side effects of the systemic treatment modalities, these flaws make the traditional chemotherapy agents unsatisfactory and often do not target specific areas of treatment. These issues are remedied by CM-NPs, which provide the drug in target areas and in a controlled manner that limits the release of the drug to internalized tumor cell sites or regions.

Vaccines against cancer have also the potential to use cell membrane-coated nanocarriers as they achieve homotypic targeting. Such nanoparticles can bind to tumor tissue that expresses the same antigens as them, thereby promoting drug retention in the local tumor and decreasing the toxic effect on normal tissue. This technique has had excellent success, especially in the management of metastatic cancers, because the nanoparticles can successfully travel excellent distances and target very challenging cancerous tissue.

Let us know if you are interested in other topics. CM-NPs are also researched for chemotherapy; however, in our cases, they are used as conjugated systems for immunotherapy, photothermal therapy, or gene therapy. For instance, immune checkpoint molecules can be delivered into the cancerous microenvironment efficiently using cancer cell membrane-coated nanoparticles instead of systemic depletion of these molecules. Likewise, RBC membrane-coated nanoparticles containing photosensitizers are intended for photothermal therapy, where the cancer cells are unable to withstand light-activated heat generation targeting only the cancer cells.

Recent Publications on “drug delivery”

Find publications on relevant topics

Overcoming Biological Barriers

One of the most arduous components of drug delivery is the biological factors armed against drug targets. The barriers include the immune status, which separates and destroys foreign objects, as well as the thick-walled structure of solid tumors. Natural membrane coating on CM-NPs uniquely enables them to overcome such challenges.

For instance, RBC-coated nanoparticles have been reported to escape the immune response, stay in the system for long, and target the area of disease. Nanoparticles that are encapsulated with platelet membranes can target sites of vascular tissue injury and inflammation, which is why they are suitable for therapy in malignancies and cardiovascular diseases. Furthermore, since the CM-NPs mimic the natural behavior of cells, these nanoparticles can get across the blood-brain barrier. This presents an effective means of treating diseases and disorders of the nervous system, which would have otherwise been impossible due to limited drug penetration.

Enhancing Drug Efficacy and Reducing Side Effects

The addition of CM-NPs is well known to improve the therapeutic action of the drugs because of enhanced bioavailability and targeting accuracy. It helps reduce the dosage needed, avoids side effects, and reduces the toxicity to the body by delivering drugs mostly to regions of the disease. The cell membrane covers have the fact of prolonging the time of blood circulation of drugs, which increases the chances of such drugs reaching their target site in the body.

For instance, CM-NPs bearing the membranes of immune cells can be employed to treat inflamed sites with anti-inflammatory drugs, avoiding adverse side effects when addressing non-inflamed areas. Likewise, nanoparticles coated with the membrane of a cancer cell can be used to intracellularly deliver chemotherapeutic agents while reducing the adverse effects that would be caused on non-target cells and tissues during chemotherapy.

Future Directions and Challenges

CM-NPs represent a new paradigm of targeted drug delivery systems; however, there are some persistent challenges in their development and clinical applications. For instance, there is a challenge with the scale-up of the membrane coating process that has to be standardized to achieve uniformity and reproducibility of results. Another important aspect that must be addressed is the containment of the membrane-coated nanoparticles during storage and transit.

In addition, not so much is yet understood about CM-NPs and the immune system. These nanoparticles may escape immune system recognition to some extent, but longitudinal biosafety and immunogenicity studies remain to be performed. Now, research is also being conducted to implement other cell types, like stem cells and immune cells, to design even more sophisticated, efficient nanoparticles.

Continuing with this evolution, through two fields of genetic engineering and synthetic biology, it may become possible to engineer cell membranes that can be made for a certain treatment. This may open doors to new generations of CM-NPs that would combine target specificity and payload functionality plus multi-functionality for the management of wide medical problems.

Conclusion

Assisted drug delivery using cell membrane-encapsulated nanoparticles is a new paradigm in drug delivery that synergizes the attributes of natural biology and nanotechnology to achieve the most potent therapeutic systems possible. These nanoparticles can effectively target cells after avoiding several biological barriers, including immune clearance, due to their properties mimicking those of natural cells. With continued improvements in research, CM-NPs will be the game changers in the management of cancer, infectious diseases, and cardiovascular disorders, among other illnesses, towards a new level of truly individual targeted therapy.

References

  1. Miao, Y., Yang, Y., Guo, L., Chen, M., Zhou, X., Zhao, Y., Nie, D., Gan, Y. and Zhang, X., 2022. Cell membrane-camouflaged nanocarriers with biomimetic deformability of erythrocytes for ultralong circulation and enhanced cancer therapy. ACS nano, 16(4), pp.6527-6540.
  2. Park, J.H., Mohapatra, A., Zhou, J., Holay, M., Krishnan, N., Gao, W., Fang, R.H. and Zhang, L., 2022. Virus‐mimicking cell membrane‐coated nanoparticles for cytosolic delivery of mRNA. Angewandte Chemie International Edition, 61(2), p.e202113671.
  3. Ai, X., Wang, D., Honko, A., Duan, Y., Gavrish, I., Fang, R.H., Griffiths, A., Gao, W. and Zhang, L., 2021. Surface glycan modification of cellular nanosponges to promote SARS-CoV-2 inhibition. Journal of the American Chemical Society, 143(42), pp.17615-17621.
  4. Zhou, J., Karshalev, E., Mundaca‐Uribe, R., Esteban‐Fernández de Ávila, B., Krishnan, N., Xiao, C., Ventura, C.J., Gong, H., Zhang, Q., Gao, W. and Fang, R.H., 2021. Physical disruption of solid tumors by immunostimulatory microrobots enhances antitumor immunity. Advanced Materials, 33(49), p.2103505.
  5. Park, J.H., Jiang, Y., Zhou, J., Gong, H., Mohapatra, A., Heo, J., Gao, W., Fang, R.H. and Zhang, L., 2021. Genetically engineered cell membrane–coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs. Science advances, 7(25), p.eabf7820.
  6. Xiao, P., Wang, J., Zhao, Z., Liu, X., Sun, X., Wang, D. and Li, Y., 2021. Engineering nanoscale artificial antigen-presenting cells by metabolic dendritic cell labeling to potentiate cancer immunotherapy. Nano Letters, 21(5), pp.2094-2103.
  7. Zhang, Y., Liao, Y., Tang, Q., Lin, J. and Huang, P., 2021. Biomimetic nanoemulsion for synergistic photodynamic‐immunotherapy against hypoxic breast tumor. Angewandte Chemie, 133(19), pp.10742-10748.

Top Experts on “drug delivery“